Treatment of Inflammatory Arthritis in Systemic Sclerosis
Joint involvement, including arthralgia, inflammatory arthritis, joint contractures and overlapping with rheumatoid arthritis, is a common manifestation and is associated with impared quality of life in systemic sclerosis (SSc). Few studies have evaluated the treatment of arthritis in SSc. Pharmacological approach includes low-dose corticosteroids, methotrexate, and hydroxychloroquine. Non-tumor necrosis factor biologics, especially rituximab and tocilizumab, may be a promising option for refractory cases.
Source: Rheumatic Disease Clinics of North America - Category: Rheumatology Authors: Cristiane Kayser, Lucas Vict ória de Oliveira Martins Source Type: research
More News: Actemra | Arthritis | Corticosteroid Therapy | Hydroxychloroquine | Methotrexate | Rheumatoid Arthritis | Rheumatology | Rituxan | Scleroderma | Study